Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

We recently caught up with Nick Karls, director of compliance at Holmes Murphy and Associates, and Nathan Cassin, pharmacy ...

Donald Trump's proposal to impose a 25% or more tariff on pharmaceutical imports into the United States holds significant ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

The decision comes in the wake of changes to Novartis' organisational structure, including the ... of upcoming generic launches and some big biosimilar products not due to reach the market until ...